Viridian Therapeutics, Inc. Common Stock VRDN
$28.49
-0.21%
at last close
Market Cap$3.24 billion
P/E Ratio—
Div Yield—
Volume4.50M
52-Week Range
$13.18$34.29
Analyst Ratings
- Consensus
- Buy — 11 Buy · 0 Hold · 0 Sell (11 analysts)
- Avg. Price Target
- $40.50 (+42.2% upside)
Key Stats
- Today's Range
- $27.86 – $29.47
- 50-Day Range
- $17.59 – $29.74
- 52-Week Range
- $13.18 – $34.29
- Volume
- 4.50 million shs
- Average Volume
- 2.56 million shs
- Market Cap
- $3.24 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.13%
- Days to Cover
- 2.75
About Viridian Therapeutics, Inc. Common Stock
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Related Stocks
Compare head-to-head: VRDN vs LLY·VRDN vs JNJ·VRDN vs ABBV·VRDN vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.